{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:38:09Z","timestamp":1769600289332,"version":"3.49.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2008,4,8]],"date-time":"2008-04-08T00:00:00Z","timestamp":1207612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,4,8]],"date-time":"2008-04-08T00:00:00Z","timestamp":1207612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s00520-008-0418-0","type":"journal-article","created":{"date-parts":[[2008,4,7]],"date-time":"2008-04-07T09:02:42Z","timestamp":1207558962000},"page":"879-889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence"],"prefix":"10.1007","volume":"16","author":[{"given":"Luis","family":"Costa","sequence":"first","affiliation":[]},{"given":"Xavier","family":"Badia","sequence":"additional","affiliation":[]},{"given":"Edward","family":"Chow","sequence":"additional","affiliation":[]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[]},{"given":"Andrew","family":"Wardley","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,4,8]]},"reference":[{"key":"418_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"418_CR2","first-page":"15","volume":"9","author":"E Adrover","year":"2005","unstructured":"Adrover E, Allepuz J, Sureda A, Domine M, Barnadas A, Constela M, Lluch A, Ruiz M, Piera J, Mayordomo JI, Morales A, Mu\u00f1oz M, Alcover J, Colomer R, Llombart A, Massutti B, Carballido J, Garrido R, Garcia R, Badia X, Lizan L, Gilabert M (2005) Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with bone metastases (BOMET-QoL). J Outcomes Res 9:15\u201327","journal-title":"J Outcomes Res"},{"key":"418_CR3","first-page":"737","volume":"36","author":"M Arianayagam","year":"2007","unstructured":"Arianayagam M, Chang J, Rashid P (2007) Chemotherapy in the treatment of prostate cancer\u2014is there a role? Aust Fam Physician 36:737\u2013739","journal-title":"Aust Fam Physician"},{"key":"418_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.eururo.2005.06.001","volume":"48","author":"G Aus","year":"2005","unstructured":"Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F (2005) EAU guidelines on prostate cancer. Eur Urol 48:546\u2013551","journal-title":"Eur Urol"},{"key":"418_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00520-004-0708-0","volume":"13","author":"SM Bang","year":"2005","unstructured":"Bang SM, Park SH, Kang HG, Jue JI, Cho IH, Yun YH, Cho EK, Shin DB, Lee JH (2005) Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer 13:515\u2013521","journal-title":"Support Care Cancer"},{"key":"418_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cger.2005.02.006","volume":"21","author":"RL Barkin","year":"2005","unstructured":"Barkin RL, Barkin SJ, Barkin DS (2005) Perception, assessment, treatment, and management of pain in the elderly. Clin Geriatr Med 21:465\u2013490, v","journal-title":"Clin Geriatr Med"},{"key":"418_CR7","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","volume":"20","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719\u20133736","journal-title":"J Clin Oncol"},{"key":"418_CR8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"JR Berenson","year":"1998","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593\u2013602","journal-title":"J Clin Oncol"},{"key":"418_CR9","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1200\/JCO.2005.04.8207","volume":"24","author":"DL Berry","year":"2006","unstructured":"Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MHA, Crawford ED (2006) Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24:2828\u20132835","journal-title":"J Clin Oncol"},{"key":"418_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1477-7525-3-78","volume":"3","author":"ML Bianchi","year":"2005","unstructured":"Bianchi ML, Orsini MR, Saraifoger S, Ortolani S, Radaelli G, Betti S (2005) Quality of life in post-menopausal osteoporosis. Health Qual Life Outcomes 3:78","journal-title":"Health Qual Life Outcomes"},{"key":"418_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","volume":"111","author":"JJ Body","year":"2004","unstructured":"Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergstrom B (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306\u2013312","journal-title":"Pain"},{"key":"418_CR12","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","volume":"14","author":"JJ Body","year":"2003","unstructured":"Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399\u20131405","journal-title":"Ann Oncol"},{"key":"418_CR13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/j.1525-1497.2001.00625.x","volume":"16","author":"ST Bogardus Jr","year":"2001","unstructured":"Bogardus ST Jr, Towle V, Williams CS, Desai MM, Inouye SK (2001) What does the medical record reveal about functional status? A comparison of medical record and interview data. J Gen Intern Med 16:728\u2013736","journal-title":"J Gen Intern Med"},{"key":"418_CR14","unstructured":"Cancer Research UK (2007) Bone mets newsletter 03: April 2007. Available at: http:\/\/www.ucl.ac.uk\/cancertrials\/trials\/rib\/Spring%2007.pdf. Accessed December 20, 2007"},{"key":"418_CR15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570\u2013579","journal-title":"J Clin Oncol"},{"key":"418_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0167-8140(02)00170-6","volume":"64","author":"E Chow","year":"2002","unstructured":"Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64:275\u2013280","journal-title":"Radiother Oncol"},{"key":"418_CR17","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129\u2013138","journal-title":"Ann Acad Med Singapore"},{"key":"418_CR18","doi-asserted-by":"crossref","unstructured":"Clemons M, Dranitsaris G, Ooi W, Cole DE (2007) A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat [Epub ahead of print]","DOI":"10.1007\/s10549-007-9583-y"},{"key":"418_CR19","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","volume":"24","author":"MJ Clemons","year":"2006","unstructured":"Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24:4895\u20134900","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"418_CR20","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(suppl):1588\u20131594","journal-title":"Cancer"},{"issue":"suppl 4","key":"418_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","volume":"9","author":"RE Coleman","year":"2004","unstructured":"Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(suppl 4):14\u201327","journal-title":"Oncologist"},{"key":"418_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/jnci\/93.7.534","volume":"93","author":"RJ Cook","year":"2001","unstructured":"Cook RJ, Major P (2001) Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 93:534\u2013538","journal-title":"J Natl Cancer Inst"},{"key":"418_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0304-3959(88)90061-9","volume":"32","author":"M Deschamps","year":"1988","unstructured":"Deschamps M, Band PR, Coldman AJ (1988) Assessment of adult cancer pain: shortcomings of current methods. Pain 32:133\u2013139","journal-title":"Pain"},{"key":"418_CR24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00520-007-0244-9","volume":"15","author":"IJ Diel","year":"2007","unstructured":"Diel IJ (2007) Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer 15:1243\u20131249","journal-title":"Support Care Cancer"},{"key":"418_CR25","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","volume":"40","author":"IJ Diel","year":"2004","unstructured":"Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergstrom B (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704\u20131712","journal-title":"Eur J Cancer"},{"key":"418_CR26","doi-asserted-by":"crossref","unstructured":"Eastham J, McKiernan J, Gleason D, Zheng M, Saad F Effect of zoledronic acid on bone pain and skeletal morbidity in patients with advanced prostate cancer: analysis by baseline pain [poster]. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology; May 13\u201317, 2005; Orlando, Florida. Abstract 4561","DOI":"10.1200\/jco.2005.23.16_suppl.4561"},{"key":"418_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.urology.2004.08.041","volume":"65","author":"E Efstathiou","year":"2005","unstructured":"Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A (2005) Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology 65:126\u2013130","journal-title":"Urology"},{"key":"418_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF02549644","volume":"24","author":"I Elomaa","year":"1992","unstructured":"Elomaa I, Kylmala T, Tammela T, Viitanen J, Ottelin J, Ruutu M, Jauhiainen K, Ala-Opas M, Roos L, Seppanen J et al (1992) Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 24:159\u2013166","journal-title":"Int Urol Nephrol"},{"key":"418_CR29","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","volume":"21","author":"DS Ernst","year":"2003","unstructured":"Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W (2003) Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21:3335\u20133342","journal-title":"J Clin Oncol"},{"key":"418_CR30","unstructured":"European Organisation for Research and Treatment of Cancer (2007) EORTC Quality of Life Group projects. Available at: http:\/\/www.eortc.be\/home\/qol\/QLGProjects.htm. Accessed July 31, 2007"},{"key":"418_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group (1990) EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208","journal-title":"Health Policy"},{"key":"418_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","volume":"78","author":"F Fulfaro","year":"1998","unstructured":"Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C (1998) The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78:157\u2013169","journal-title":"Pain"},{"key":"418_CR33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1179\/joc.2005.17.5.555","volume":"17","author":"F Fulfaro","year":"2005","unstructured":"Fulfaro F, Leto G, Badalamenti G, Arcara C, Cicero G, Valerio MR, Di Fede G, Russo A, Vitale A, Rini GB, Casuccio A, Intrivici C, Gebbia N (2005) The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother 17:555\u2013559","journal-title":"J Chemother"},{"key":"418_CR34","unstructured":"Harris K, Chow E (2006) Bone metastases module. Available at: http:\/\/www.eortc.be\/home\/qol\/Presentations%20of%20past%20meetings\/Southampton%20Nov%202006\/Chow_Bone_mets_module_short_Nov2006.pdf. Accessed July 31, 2007"},{"key":"418_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","volume":"5","author":"A Heidenreich","year":"2002","unstructured":"Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5:231\u2013235","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"418_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/00005392-200101000-00033","volume":"165","author":"A Heidenreich","year":"2001","unstructured":"Heidenreich A, Hofmann R, Engelmann UH (2001) The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165:136\u2013140","journal-title":"J Urol"},{"issue":"suppl","key":"418_CR37","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1016\/S1359-6349(03)90923-2","volume":"1","author":"A Heidenreich","year":"2003","unstructured":"Heidenreich A, Ohlmann C, Olbert P, Hegele A (2003) High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer [abstract]. Eur J Cancer Suppl 1(suppl):S270 Abstract 897","journal-title":"Eur J Cancer Suppl"},{"key":"418_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1590\/S1677-55382003000300006","volume":"29","author":"F Hering","year":"2003","unstructured":"Hering F, Rodrigues PRT, Lipay M (2003) Clodronate for treatment of bone metastases in hormone refractory prostate cancer. Int Braz J Urol 29:228\u2013233","journal-title":"Int Braz J Urol"},{"key":"418_CR39","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057","journal-title":"J Clin Oncol"},{"key":"418_CR40","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","volume":"16","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038\u20132044","journal-title":"J Clin Oncol"},{"key":"418_CR41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.clon.2004.07.005","volume":"16","author":"PJ Hoskin","year":"2004","unstructured":"Hoskin PJ (2004) The RIB trial. Clin Oncol (R Coll Radiol) 16:445\u2013446","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"418_CR42","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1023\/A:1012506426440","volume":"12","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Purohit OP, Heatley S, Herling C, Coleman RE (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12:1433\u20131438","journal-title":"Ann Oncol"},{"key":"418_CR43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106\u2013130","journal-title":"CA Cancer J Clin"},{"issue":"suppl 2","key":"418_CR44","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.ejon.2007.07.002","volume":"11","author":"N Kinnane","year":"2007","unstructured":"Kinnane N (2007) Burden of bone disease. Eur J Oncol Nurs 11(suppl 2):S28\u2013S31","journal-title":"Eur J Oncol Nurs"},{"key":"418_CR45","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23:3314\u20133321","journal-title":"J Clin Oncol"},{"key":"418_CR46","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00198-004-1762-7","volume":"16","author":"P Lips","year":"2005","unstructured":"Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16:447\u2013455","journal-title":"Osteoporos Int"},{"key":"418_CR47","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11864-005-0023-0","volume":"6","author":"A Lipton","year":"2005","unstructured":"Lipton A (2005) Management of bone metastases in breast cancer. Curr Treat Options Oncol 6:161\u2013171","journal-title":"Curr Treat Options Oncol"},{"key":"418_CR48","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082\u20131090","journal-title":"Cancer"},{"key":"418_CR49","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","volume":"22","author":"I Mancini","year":"2004","unstructured":"Mancini I, Dumon JC, Body JJ (2004) Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22:3587\u20133592","journal-title":"J Clin Oncol"},{"key":"418_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.hoc.2007.03.001","volume":"21","author":"EL Mayer","year":"2007","unstructured":"Mayer EL, Burstein HJ (2007) Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 21:257\u2013272","journal-title":"Hematol Oncol Clin North Am"},{"key":"418_CR51","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","volume":"20","author":"HD Menssen","year":"2002","unstructured":"Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20:2353\u20132359","journal-title":"J Clin Oncol"},{"key":"418_CR52","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.1995.13.4.929","volume":"13","author":"N O'Rourke","year":"1995","unstructured":"O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA (1995) Double-blind, placebo-controlled, dose\u2013response trial of oral clodronate in patients with bone metastases. J Clin Oncol 13:929\u2013934","journal-title":"J Clin Oncol"},{"key":"418_CR53","first-page":"49","volume":"17","author":"E Ozyuvaci","year":"2005","unstructured":"Ozyuvaci E, Altan A, Demir C (2005) [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer]. Agri 17:49\u201353","journal-title":"Agri"},{"key":"418_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/ard.2004.034611","volume":"65","author":"I Pande","year":"2006","unstructured":"Pande I, Scott DL, O'Neill TW, Pritchard C, Woolf AD, Davis MJ (2006) Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis 65:87\u201392","journal-title":"Ann Rheum Dis"},{"issue":"suppl","key":"418_CR55","first-page":"694s","volume":"24","author":"C Ripamonti","year":"2006","unstructured":"Ripamonti C, Fagnoni E, Campa T, Giardina V, Brunelli C, De Conno F (2006) Pain on movement and pain on rest decrease after zoledronic acid infusion in patients with bone metastases due to breast or prostate cancer [abstract]. J Clin Oncol 24(suppl):694s Abstract 18582","journal-title":"J Clin Oncol"},{"key":"418_CR56","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/sj.pcan.4500752","volume":"7","author":"P Rodrigues","year":"2004","unstructured":"Rodrigues P, Hering F, Campagnari JC (2004) Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis 7:350\u2013354","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"418_CR57","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613\u20132621","journal-title":"Cancer"},{"key":"418_CR58","unstructured":"Saad F, Gleason D, Murray R, Venner P, Tchekmedyian NS, Lacombe L, Chin J, Vinholes J, Goas JA, Chen B-L, Seaman J (2003) Zoledronic acid is well tolerated for up to 24\u00a0months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone [poster]. Presented at: American Urological Association Annual Meeting; April 26\u2013May 1, 2003; Chicago, Illinois. Abstract 1472"},{"key":"418_CR59","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"418_CR60","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879\u2013882","journal-title":"J Natl Cancer Inst"},{"key":"418_CR61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.archger.2005.10.006","volume":"43","author":"A Santangelo","year":"2006","unstructured":"Santangelo A, Testai M, Barbagallo P, Manuele S, Di Stefano A, Tomarchio M, Trizzino G, Musumeci G, Panebianco P, Maugeri D (2006) The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population. Arch Gerontol Geriatr 43:187\u2013192","journal-title":"Arch Gerontol Geriatr"},{"key":"418_CR62","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","volume":"21","author":"EJ Small","year":"2003","unstructured":"Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21:4277\u20134284","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"418_CR63","first-page":"10","volume":"22","author":"H Sonoo","year":"1995","unstructured":"Sonoo H, Shimozuma K, Kurebayashi J, Ohta K, Kiyono T (1995) [Systemic therapy, pain relief and quality of life of breast cancer patients with bone metastasis]. Gan To Kagaku Ryoho 22(suppl 1):10\u201315","journal-title":"Gan To Kagaku Ryoho"},{"key":"418_CR64","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0021-9681(81)90058-8","volume":"34","author":"WO Spitzer","year":"1981","unstructured":"Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, Battista RN, Catchlove BR (1981) Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34:585\u2013597","journal-title":"J Chronic Dis"},{"key":"418_CR65","unstructured":"Stanculeanu DL, Minea LN, Cringeaunu A, Anghel R (2006) Zoledronic acid treatment in osteocondensant bone metastasis prostate cancer patients [abstract]. Presented at: 2006 ASCO Prostate Cancer Symposium; February 24\u201326, 2006; San Francisco, California. Abstract 289"},{"key":"418_CR66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3111\/200710027039","volume":"10","author":"A Sureda","year":"2007","unstructured":"Sureda A, Isla D, Cozar JM, Ruiz M, Domine M, Margeli M, Adrover E, Ramos M, Pastor M, Martin A, Llombart A, Massutti B, Munoz M, Barnadas A, Fernandez J, Colomer R, Allepuz J, Gilabert M, Badia X (2007) Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia. J Med Econ 10:27\u201339","journal-title":"J Med Econ"},{"key":"418_CR67","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846\u2013854","journal-title":"J Clin Oncol"},{"key":"418_CR68","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1023\/A:1015632114068","volume":"11","author":"J Tidermark","year":"2002","unstructured":"Tidermark J, Zethraeus N, Svensson O, Tornkvist H, Ponzer S (2002) Femoral neck fractures in the elderly: functional outcome and quality of life according to EuroQol. Qual Life Res 11:473\u2013481","journal-title":"Qual Life Res"},{"key":"418_CR69","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s001980200100","volume":"13","author":"A Trombetti","year":"2002","unstructured":"Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R (2002) Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 13:731\u2013737","journal-title":"Osteoporos Int"},{"key":"418_CR70","first-page":"701","volume":"88","author":"M Tubiana-Hulin","year":"2001","unstructured":"Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E (2001) Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer 88:701\u2013707","journal-title":"Bull Cancer"},{"key":"418_CR71","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijrobp.2006.08.022","volume":"67","author":"V Vassiliou","year":"2007","unstructured":"Vassiliou V, Kalogeropoulou C, Christopoulos C, Solomou E, Leotsinides M, Kardamakis D (2007) Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 67:264\u2013272","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"418_CR72","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10585-007-9066-x","volume":"24","author":"V Vassiliou","year":"2007","unstructured":"Vassiliou V, Kalogeropoulou C, Giannopoulou E, Leotsinidis M, Tsota I, Kardamakis D (2007) A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin Exp Metastasis 24:169\u2013178","journal-title":"Clin Exp Metastasis"},{"key":"418_CR73","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1023\/A:1008238422151","volume":"8","author":"JJF Vinholes","year":"1997","unstructured":"Vinholes JJF, Purohit OP, Abbey ME, Eastell R, Coleman RE (1997) Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 8:1243\u20131250","journal-title":"Ann Oncol"},{"key":"418_CR74","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","volume":"9","author":"CL Vogel","year":"2004","unstructured":"Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L, Hohneker JA (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9:687\u2013695","journal-title":"Oncologist"},{"key":"418_CR75","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","volume":"92","author":"A Wardley","year":"2005","unstructured":"Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869\u20131876","journal-title":"Br J Cancer"},{"key":"418_CR76","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","volume":"42","author":"KP Weinfurt","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA (2004) Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42:164\u2013175","journal-title":"Med Care"},{"key":"418_CR77","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579\u2013584","journal-title":"Ann Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-008-0418-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-008-0418-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-008-0418-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-008-0418-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T01:08:00Z","timestamp":1652663280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-008-0418-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,8]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["418"],"URL":"https:\/\/doi.org\/10.1007\/s00520-008-0418-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,8]]},"assertion":[{"value":"19 October 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}